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Abstract
Objective: Assessment of the use of oral anticoagulants in patients with ischemic stroke and atrial fibrillation in the Republic of Moldova.  Methods: A 
retrospective study of all patients hospitalized with stroke during one-year period in a municipal hospital.  Results: Out of 735 patients with ischemic stroke, 
atrial fibrillation was noted in 28.4% (206/189).  The majority were female, 57.8% (119/206) with the mean age of 70.1 ± 0.65 years.  Ninety two (92.5%) of 
all patients had a high thromboembolic risk, 5.8% - medium and 1% - low risks.  In the medium risk group the rate of antithrombotic treatment represented 
88.9%.  Even if about 92% were considered to have a high risk for thromboembolic complications, 60% were eligible for anticoagulation, but only 7.1% 
received it prior to the stroke.  After the cerebrovascular accident all patients were considered to be at high risk, but only 14.8% were anticoagulated and 
only 26.6% (4/15) had the therapeutic International Normalized Ratio (INR) in the range 2.0-3.0.  Physical disability and non-compliance were the most 
frequent reasons for noncompliance to anticoagulation.  At the next visit 65.2% were receiving aspirin, and 20% were not receiving any antithrombotic 
medication.  No hemorrhagic complications were reported after 14 months of follow up.  Conclusions: A significant proportion of patients (92.9%) with 
atrial fibrillation and high antithrombotic risk were not anticoagulated before ischemic stroke for various reasons: underestimation of antithrombotic 
benefit and fear of hemorrhagic complications from physician’s behalf and difficulties in systematic INR monitoring from patient’s behalf.
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Антитромботическое лечение больных с мерцанием предсердий,  
перенесших ишемический инсульт
Цель: определить процент применения непрямых антикоагулянтов (НАК) у больных c мерцанием предсердий (МП) и ишемическим 
инсультом.  Методы: ретроспективное исследование всех больных с острым ишемическим инсультом, поступивших в одну городскую 
больницу, в течение одного года.  Результаты: из 735 больных с ишемическим инсультом, МП было выявлено у 28,4% (206/735) больных 
среднего возраста (70,1 ± 0,65 лет), из которых большинство были женщины – 57.8% (119/206).  Из всех больных 92,5% были с высоким 
тромбоэмболическим риском, 5,8% - средним и 1% - с низким.  Процент назначения антитромботического лечения в группе больных со средним 
риском составил 88,9%.  Из больных с высоким риском, в среднем 60% было показано назначение антикоагулянтов, но лишь 7,1% получили 
их до развития инсульта.  После инсульта все пациенты считались с высоким тромбоэмболическим риском, но лишь 14,8% получали НАК, 
из которых 26,6% (4/15) поддерживали INR (2,0-3,0), тогда как реальные возможности получения антикоагулянтов было у 40,6% больных. 
Физическая нетрудоспособность и неспособность соблюдать рекомендации врача были самыми частыми причинами не назначения НАК.  На 
повторном визите 65,2% больных получали аспирин, а остальные 20% не получали никакого антитромботического лечения.  За 14 месяцев 
наблюдения не было зарегистрировано ни одного случая кровотечения.  Заключение: значительная часть (92,9%) больных с МП и высоким 
тромбоэмболическим риском не принимали НАК до развития инсульта по разным причинам: недооценка преимуществ антикоагулянтной 
терапии, опасность геморрагических осложнений, необходимость регулярной проверки уровня антикоагуляции.
Ключевые слова: мерцание предсердий, ишемический инсульт, антитромбическое лечение.
Introduction
Atrial fibrillation (AF) is a common rhythm disturbance in 
the daily medical practice in Republic of Moldova.  The most 
serious complication associated with AF is cerebral or systemic 
(non - cerebral) thromboembolism.  This rhythm disturbance 
increases stroke risk 4-5 fold in any age group. Out of the total 
ischemic strokes, about 20-25% are cardioembolic and almost 
60% of them due to AF, therefore, nearly 15% of the total 
number of ischemic strokes are due to AF.  The annual rate of 
strokes in nonvalvular AF, without anticoagulant treatment, 
is 4.5% for the first thromboembolic event and 12% per year 
for recurrent events [1].  Thromboembolic risk is associated 
with an annual rate of systemic embolisms of about 0.3-0.8%, 
their frequency being substantially elevated in AF.  Significant 
and independent influence of AF on stroke risk is confirmed 
by the data of numerous randomized trials.  Meta-analysis 
of multiple studies shows a reduction of approximately 68% 
in thromboembolic events on treatment with warfarin, in 
patients with AF [2].  Strokes due to AF have a more severe 
evolution than other forms of ischemic strokes, being associ-
ated with a higher mortality (nearly 30%) and a high rate of 
irrecoverable and invalidating neurological consequences [3].
Despite clinical evidence, several trials in USA and Europe 
showed that only 25-50% of patients with AF receive anti-
thrombotic therapy corresponding to the risk [4].  The causes 
of this discrepancy between clinical practice and clinical trials 
are not easy to explain and it is not known whether the same 
situation is in RM.
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In this work we have proposed as an aim to examine the 
use of anticoagulants and of the factors that influence it in 
patients with AF and ischemic stroke in a medical institution 
from the Republic of Moldova.
Material and methods
All patients with stroke, hospitalized in the hospital “SF. 
TREIME” from Chisinau have been studied retrospectively 
during the year of 2004.  For inclusion in the study the pa-
tients have been identified in the data based on stroke from 
that hospital.  At the first step of the research, the details on 
patients were obtained from the medical cards.  The diagnosis 
of ischemic stroke was established beforehand by neurologists, 
and the ECG was evaluated by a cardiologist.  The patients 
have been observed for 14.2 ± 0.74 months.  The following 
information, during observation, was obtained through 
active examination in Institute of Cardiology; for immobile 
patients – at their homes, being completed by discussions with 
family doctors and relatives, also by the study of ambulatory 
medical cards.
Results
Seven hundred thirty-five patients with acute ischemic 
stroke were hospitalized during the study, 206 of the patients 
(28.4%) had AF confirmed through ECG.  The characteristics 
of these patients at hospitalization are listed in tab. 1.
Table 1
Characteristics of patients  
with stroke and AF at trial inclusion
Parameters Patients with stroke  and AF, n = 206
Age, years
Women
Chronic atrial fibrillation
Arterial hypertension
Vascular pathology
Rheumatic valvulopathies
Congestive heart failure
Diabetes mellitus
Previous thromboembolic event
≥ 2 strokes 
Period between strokes, months
Mortality in the hospital
70.1 ± 0.65
57.8% (119)
70.4% (145)
87.4% (180)
82% (169)
9.2% (19)
96.1% (198)
29.1% (60)
30.1% (62)
4.4% (9)
27.2 ± 5.5
30.6% (63)
The mean age of subjects with AF was 70.1 ± 0.65 years 
(age range 34-91 years), the third part of them (29.1%) being 
aged ≥ 75 years.  Among subjects with rhythm disturbances 
and stroke, more than a half was of female gender 57.8% (119). 
The great majority of patients with AF (84%) have suffered 
an established ischemic stroke.
The prevalence of AF in patients with stroke was 28.4%, 
and it varied depending on the type of cerebral ischemia, 
followed by transient ischemic attack (TIA) with 25%, 
lacunar stroke – 15.4% and minor stroke – 13.2%.  Out of 
206 patients with AF, chronic and persistent forms were 
present in 145 individuals (70.4%), paroxystic AF in 50 
(24.3%) and atrial flutter in 11 patients (5.3%).  It is nota-
ble, that 8 patients (3.9%) had AF, determined for the first 
time at hospitalization.
Cardiovascular pathology associated with atrial fibrillati-
on increases the risk for stroke and aggravates its evolution, 
leading to the appearance of serious consequences.  The de-
tailed analysis of patients with ischemic stroke, in this trial, 
revealed the presence of associated diseases, which included 
associated cardiovascular pathology and diabetes mellitus, 
in most patients with AF (99.5%), with the exception of a 
man.  Arterial hypertension was found in 87.4% of patients; 
vascular diseases, presented as stable angina pectoris, AMI, 
previous MI or diseases of peripheral vessels, were found in 
88% of patients; cardiac failure of different grades - in 96.1% 
of patients; diabetes mellitus was found in 29.1% of patients, 
and 9.2% of subjects were diagnosed with rheumatic valvu-
lopathy.  A significant part of patients (30.1%) had previous 
thromboembolic events, in 4.4% of cases being multiple (≥ 2). 
The mean period between thromboembolic events lasted for 
26.8 ± 2.6 months; 14.5% of patients have suffered a repeated 
stroke in less than a month from the anterior thromboembolic 
episode, and 61.3% individuals-in a year.
The patients were considered to be at high risk if at least 2 
risk factors were identified by investigators for AF, in a meta-
analysis of 5 randomized trials: (age > 75 years, hypertension, 
HF, diabetes mellitus) or ischemic stroke or previous TIA – 
CHADS2 score, tab. 2.
Table 2
The distribution of CHADS2 score 
and the evaluation of thromboembolic risk
Points Risk AF + stroken = 206
Deceased
n = 63
    Survivors
n = 143
0
1
≥ 2
Low
Moderate
High
2 (1.1%)
12 (6.4%)
173 (92.5%)
0%
1 (1.7%)
57 (98.3%)
2 (1.6%)
11 (8.5%)
116 (89.9%)
RV High 19 (9.2%) 5 (7.9%) 14 (9.8%)
RV- rheumatic valvulopathy.
The data included in the table show that most of the 
patients – 92.5%, have scored more than ≥ 2 points from the 
proposed score, which corresponds to a high thromboembolic 
risk with need for chronic therapy with oral anticoagulants, 
5.8% of patients with AF presented a moderate risk, having the 
necessity of chronic treatment with antiaggregants or optional 
with warfarin and only about 1% of patients with AF did not 
have any risk factors for major thromboembolic events, being 
classified in the low risk group with aspirin considered suffi-
cient for an adequate thromboembolic protection.  A separate 
group was formed by 19 patients with rheumatic valvulopathy 
(9.2%) – pathology which implies a high thromboembolic risk 
and which constitutes an absolute indication for the adminis-
tration of indirect anticoagulants, independently of the gained 
points according to CHADS2 score.  Studying CHADS2 score 
in patients with AF it was noted that out of 12 patients with 
moderate risk, (8.3%) patients deceased, and out of patients 
of high risk 62 (32.3%) deceased, 5 (26.3%) of them suffering 
from rheumatic valvulopathies.
The examination of ambulatory medical cards at the 2nd 
research step (repeated examination) made possible the deter-
mination of the rate of prescribing antithrombotic treatment 
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in the period before the certain thromboembolic event and 
gave the possibility to appreciate the extent of correspondence 
to guideline recommendations regarding this medication.  The 
analysis of correlation between the risk evaluated by CHADS2 
score and the applied antithrombotic treatment was possible 
in 108 patients examined repeatedly.  As a consequence, it was 
concluded that none of these patients had a low thromboem-
bolic risk, moderate risk was present in 9 patients (8.33%), 
and high risk for stroke had 99 patients (91.7%).
The rate of patients with moderate risk, administrating 
antithrombotic treatment corresponding to risk gradation 
constituted 88.9% (6 patients (66.7%) received aspirin and 2 
patients (22.2%) – thrombostop).  About 58 patients (58.6%), 
with CHADS2 score ≥ 2, administered antiplatelet drugs and 
only 7 patients (7.1%) had the benefit, before the stroke, of 
treatment with oral anticoagulants that corresponds to an 
adequate antithrombotic protection for this category of pa-
tients.  The rate of antithrombotic treatment appreciated in 
dependence of the estimated risk for major thromboembolic 
events in patients with AF is represented in fig. 1.
Therefore, in the period before stroke, 99 (91.7%) patients 
had a high risk and absolute indications for the prevention 
with oral anticoagulants and only 9 (8.3%) patients had 
relative indications for anticoagulants use, presenting mo-
derate thromboembolic risk.  In this period, in ambulatory 
conditions, only 9 (8.3%) patients (7 of which had high risk, 
2 of them moderate risk) administered preventive treatment 
with oral anticoagulants.  Only 2 (1.8%) patients had PI in 
the recommended therapeutic range (40-60%), assuring 
an optimal antithrombotic protection, the other 7 patients 
presented values of PI greater than 60%. INR index was not 
determined in any patient.  In the group of patients with val-
vular AF only 4 patients received indirect anticoagulants.  The 
other 10 patients with AF and mitral valve stenosis remained 
unprotected, the antithrombotic treatment lacking in the 
ambulatory medical card.
After discussions with the family doctors and the study 
of medical documentation it was appreciated that only 64 
(59.3%) patients had real possibilities to receive indirect 
anticoagulants, and regarding the rest of them: 17.6% were 
incompliant, 7.4% did not have the possibility to monitor co-
agulation parameters having an advanced grade of disability, 
11.1% had uncontrolled hypertension, 3.7% - gastrointestinal 
pathology with high bleeding potential, and a patient (0.9%) 
had previously a major hemorrhagic episode, tab. 3.
Fig. 1.  The rate of antithrombotic medication in patients with different degrees of thromboembolic risk.
Table 3
Contraindications for administration of oral 
anticoagulants
Contraindications Before stroke, n = 108
After stroke, 
n = 101
Lack of compliance
Great disability
Uncontrolled hypertension
Gastrointestinal pathology
Previous bleedings
Recent stroke
Oncological pathology
Real possibilities  
to receive oral anticoagulants
17.6% (19)
7.4% (8)
11.1% (12)
3.7% (4)
0.9% (1)
-
-
59.3% (64)
27.7% (28)
15.8% (16)
4.9% (5)
5.9% (6)
   1% (1)
   2% (2)
   2% (2)
 40.6% (41)
Treatment with aspirin was received by 64 (59.3%) pati-
ents (6 with moderate risk and 58 with high risk). Absolute 
contraindications had only a patient with gastrointestinal 
acute pathology associated with recidivating bleedings.  Six 
(5.6%) patients presented relative contraindications for 
aspirin, having gastrointestinal pathologies, and a patient 
presented allergic reaction to non-steroid anti-inflammatory 
drugs.  After the preventive treatment, 2 patients presented 
exacerbations of gastrointestinal pathology, and a woman had 
a hemorrhagic episode.
In this way, based on the received results it can be stated 
that out of 108 patients who needed antithrombotic treatment, 
only 14% administered antithrombotic medication in accor-
dance with the risk, in the period before thromboembolic 
events that is shown in fig. 2.
According to CHADS2 score, all patients evaluated re-
peatedly were included in the group of patients with high 
thromboembolic risk and had absolute indications for the ad-
ministration of oral anticoagulant therapy.  Only 15 (14.85%) 
patients with stroke and AF have been recommended and 
were administering anticoagulant therapy, only in 4 (3.96%) 
patients PI reached the target values of (40-60%) and INR 2.0-
3.0, in this way being protected by repeated thromboembolic 
events, the data being graphically presented in fig. 3.
Analyzing the indications, contraindications, degree of 
physical disability of patients, possibility of PI monitoring in 
policlinics conditions and patient compliance, real possibilities 
of antithrombotic preventive treatment were appreciated for 
only 41 (40.6%) of interrogated patients, the rest of them: 
28 (27.7%) were incompliant to treatment, 16 (15.8%) had 
marked physical disabilities, 6 (5.9%) presented exacerbations 
of gastrointestinal pathology, 5 (4.95%) had uncontrolled 
hypertension, 1 patient had an acute bleeding, 2 patients had 
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Fig. 2.  The rate of adequate antithrombotic treatment.
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Fig. 3.  The rate of patients who received anticoagulants at repeated examination.
repeated stroke during the first month after previous stroke, 
and in 2 patients oncological pathology was suspected.
Sixty-six (65.3%) patients were administered aspirin, 
and a patient received clopidogrel.  Nine patients did not 
receive aspirin because of gastrointestinal pathology, a pati-
ent presented allergy to aspirin, and 25 patients did not use 
antiaggregants, in this way ignoring medical indications, 
or because of the fact that such recommendations were not 
accepted, or administered irregularly antiplatelet therapy. 
It is notable that, aspirin was administered to 67.5% of the 
patients with chronic AF and 15.8% with paroxystic AF, 
and oral anticoagulants were administrated only to patients 
with chronic form of AF.  On background treatment with 
antithrombotics 2 patients developed complications of mild 
and moderate gravity: a patient presented gastrointestinal 
bleeding, and another one developed acute erosions of 
gastric mucosa being on aspirin.
Therefore, after repeated stroke the rate of therapy with 
oral anticoagulants increased 2-fold, but it still remained 
Fig. 4.  The rate of oral anticoagulant treatment.
insufficient in patients with AF and at high thromboembolic 
risk, fig. 4.
During observation period (14.2 ± 0.74 months) the rate 
of thromboembolic recurrences was 29.6% (37/125), and of 
late deaths – 35.2% (44/125).  In this period no hemorrhagic 
complications as a consequence of oral anticoagulant therapy 
administration were registered.
Discussions
Atrial fibrillation is the most common rhythm disturbance 
in clinical medical practice.  Annual incidence of stroke is 
6-fold higher in patients with AF, comparative to individuals 
of similar age and sinus rhythm [5].  Many randomized tri-
als have shown the efficacy of anticoagulants in preventing 
stroke in patients with AF [4].  In a general analysis on AF 
the investigators have shown that warfarin significantly re-
duces thromboembolic risk, from 4.5% to 1.45% annually, 
with relative risk reduction by 68% [6].  The benefic effect of 
warfarin has been obtained with a minimal risk elevation for 
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hemorrhagic complications, 1.2% in comparison with 1% for 
placebo.  In absolute terms approximately 90 ischemic stro-
kes are prevented, if 1000 patients with high risk are treated 
during 1-year period.
Recently guidelines and articles have been published on 
anticoagulation in AF.  In clinical practice the rate of antico-
agulant use still remains to be suboptimal.  The frequency of 
oral anticoagulant use in patients without contraindications 
varies between 15.2 and 78.8%, warfarin being prescribed 
more often to young patients (< 65 years) [7].  Our study 
confirms these observations and adds information on cir-
cumstances which affect the clinic decision making regarding 
anticoagulant administration.
Our results show a resistance in use of indirect anticoa-
gulants in patients with AF and high thromboembolic risk, 
with only 7.1% prescriptions before stroke.  The retrospective 
nature of the study makes the evaluation of reasons difficult, 
though the registration of contraindications for oral anticoa-
gulants was not evident at the examination of medical cards. 
These data are lower than the results of Kalro et al. trial in 
Great Britain.  They reported that only 31% of patients with 
AF, for at least 12 months, with a major risk factor, were 
anticoagulated at the moment of enrollment in the study 
[8].  In addition, Jackson et al. have reported similar data in 
Tansania, with only 34% patients with AF with high risk who 
received warfarin [9].
Why not is warfarin used enough, despite important ar-
guments which support its benefit in AF?  One of the possible 
reasons is that clinical trials are not considered representative 
for “the real world”, with a greater rate of men and younger 
patients.  Because of monitoring difficulties the patients often 
refuse the administration of warfarin.  These refusals have 
been documented rarely in the studied medical cards, being 
found only for 1.2% patients.  The physicians can also be 
reserved in the initiation of treatment with warfarin, because 
of the time lost in order to make the patient understand why 
and in which way to administer this drug.  Some specialists 
even doubt the application in their daily practice of the re-
commendations from guidelines.
The apparent lack of trust of physicians in treatment with 
warfarin, in patients with AF, can be partially explained throu-
gh exaggerated care of hemorrhagic risks and underestimation 
of stroke risk.  Another reason is that the guideline for the 
management of patients with AF, which was valid in 2004, 
presented relatively other indications for anticoagulation. 
In fact, the lack of knowledge on recommended antithrom-
botic therapy can partially explain why the patients treated 
in neurological departments had fewer chances to receive 
oral anticoagulation.  There is still the possibility of some 
underestimations regarding the real number of patients with 
contraindications for anticoagulation.
After discussions with the family doctors and examination 
of medical documentation it has been appreciated that only 
64 (59.3%) patients had real possibilities to receive indirect 
anticoagulants, and 17.6% were incompliant, 7.4% did not 
have the possibility to monitor coagulation parameters, 
having an advanced degree of disability, 11.1% had uncon-
trolled hypertension, 3.7% - gastrointestinal pathology with 
high bleeding potential, and a patient (0.9%) had previously 
a major hemorrhagic episode.
Unified analysis of 5 major randomized trials has shown 
that advanced age is an independent risk factor for stroke [6]. 
The risk for stroke in AF starts to increase from the age of 
65 years, though, it is clear that the risk for stroke is signifi-
cant in those ≥ 75 years, who have a greater benefic effect at 
administration of vitamin K antagonists, comparative to the 
effect of aspirin [10, 11].  With aging, the relative efficiency of 
antiplatelet medication in preventing stroke reduces in pati-
ents with AF, which does not happen with oral anticoagulants. 
AF is the most frequent reason of a disabilitating stroke in 
elderly women [4].  The resistance of physicians in starting 
oral anticoagulants in elderly patients is generally considered 
to be related to a higher risk for hemorrhagic complications. 
The investigators from SPAF II trial have shown that the risk 
of major bleeding was substantially higher in patients with AF 
> 75 years, comparative with younger patients, who received 
anticoagulation therapy at the same extent [4].  Unlike this 
one, the unified analysis of 5 trials demonstrated only a single 
intracerebral bleeding among 223 patients of more than 75 
years, who received warfarin [6].  But it is known the fact 
that the incidence of intracerebral bleeding increases with 
ageing, even in people who do not use oral anticoagulants. 
It is possible, that the elevated risk for intracerebral bleeding 
in the elderly could be caused not by warfarin administrati-
on, but by physiological changes in the coagulation process 
happening with ageing [12].  Although our study group was 
small, there were not reported any hemorrhagic complications 
in an observational period of 14.2 months.
In the case of initiation of warfarin therapy it is impor-
tant to obtain the therapeutic level of anticoagulation (INR 
2.0-3.0).  Recent guidelines recommend a lower intensity of 
anticoagulation in patients > 75 years, with INR 2.0 [13].  INR 
level has to be intensely monitored in the elderly patients, in 
order to minimize not only the risk of oral anticoagulants 
over dosage, but also of suboptimal therapy, in which the 
protection for thromboembolic events is lower [14].  In our 
trial, at the moment of hospitalization, only 2 out of  9 patients 
on oral anticoagulants had INR within the range 2.0-3.0, and 
at repeated examination - 4 of 15.
Finally, it is important to mention that a significant pro-
portion of our patients have initiated anticoagulation after 
stroke.  The reason for this change in the management of 
patients at high risk before the event is not entirely clear, 
although individual differences can exist in medical practice.
Evaluating the indications, contraindications, physical 
capacities of patients, as well as technical conditions of po-
liclinics, it has been determined that only 40.6% of reevalu-
ated patients after stroke had real possibilities to administer 
preventive antithrombotic treatment.  Among those who did 
not receive oral anticoagulation therapy – 27.7% were abso-
lutely incompliant to treatment, 15.8% had marked physical 
disabilities, 5,9% presented exacerbation of gastrointestinal 
Nr. 3 (321), 2011
30
pathology, 4,9% had uncontrolled hypertension, 1 woman 
suffered from frequent metrorrhagies, 2 patients have recently 
had acute stroke, and 2 patients were suspect for oncologic 
pathology.  In 65.3% patients aspirin was recommended.
In the future, through inclusion of some additional fac-
tors it may be possible to determine a more exact rule for 
appreciation of thromboembolic risk.  For example, systolic 
dysfunction of the left ventricle found at trans-thoracic 2D 
Echo-CG is an independent risk factor for stroke in AF [15]. 
It is also probable that hormonal substitutive therapy [16] and 
smoking [15] increase risk for stroke in AF, while moderate 
alcohol consumption reduces it [16].  Finally, the next studies 
will determine whether the biologic markers of inflammation 
(for ex. C-reactive protein) or endothelial dysfunction (for ex. 
von Willebrand factor) could help clinicians in risk prediction 
in the population with AF and ease the decision to initiate oral 
anticoagulant therapy.
In conclusion, despite of the limitations of a small retros-
pective single-centered trial, our data show that anticoagulant 
therapy is insufficiently used in patients with AF and high 
thromboembolic risk, in Republic of Moldova.  The reasons 
are not clear, but in practical conditions, medical science based 
on evidence is not always applicable.  Recent data confirm 
the benefits of anticoagulation in conditions outside of trials. 
Therapy with warfarin needs to be considered in all patients 
with AF and high thromboembolic risk, and advanced age 
itself should not be referred to as an absolute contraindication 
for oral anticoagulation.
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